The presentation of positive clinical data for EVT801, particularly in a challenging area like high grade serous ovarian cancer, is likely to enhance investor sentiment towards Kazia Therapeutics. The successful completion of Phase 1 with identified doses for Phase 2 suggests progress in their drug development, which is crucial for a biotech company. This news is directly relevant to KZIA as it highlights advancements in their product pipeline, potentially impacting their stock price positively.